5-Amino-1MQ complete guide

5-Amino-1MQ (chemically 5-amino-1-methylquinolin-1-ium iodide) is a small molecule, not a peptide. This is the most important framing point for the entire article: where the rest of the TogoPeptide research-compound catalog is dominated by peptide chemistry, 5-Amino-1MQ is a quinolinium-class organic compound — a synthetic small-molecule research probe developed as a selective inhibitor of Nicotinamide N-Methyltransferase (NNMT). We include it in the metabolic-research deep-dive series because the biology it targets sits squarely inside the same NAD+/methylation/adipose-research space that defines the broader Longevity and Fat Loss research lines, and because researchers working on peptide approaches to metabolic homeostasis routinely want a small-molecule complement for mechanistic-dissection arms.

The biology 5-Amino-1MQ targets is a single, well-characterised enzyme. NNMT catalyses the transfer of a methyl group from S-adenosyl methionine (SAM) — the universal cellular methyl donor — onto nicotinamide, producing 1-methylnicotinamide (1-MNA) and S-adenosyl homocysteine (SAH). The net consequence of this single enzymatic step is the simultaneous consumption of two metabolically-valuable substrates: nicotinamide is removed from the salvage pathway that regenerates NAD+, and SAM is removed from the methylation pool that supports DNA, histone, and protein methylation. Elevated NNMT expression is documented in obese adipose tissue and in liver, and is hypothesised to contribute to metabolic dysfunction by depleting both NAD+ and SAM pools at once. 5-Amino-1MQ inhibits NNMT, theoretically preserving both pools — and the published research-animal-model literature documents body-weight reductions and metabolic-homeostasis improvements in obesity research models when the enzyme is pharmacologically inhibited.

Quick reference — 5-Amino-1MQ identifiers

Property	5-Amino-1MQ
Class	Small-molecule NNMT inhibitor (quinolinium scaffold) — not a peptide
Synonyms	5-Amino-1MQ, 5A1MQ, 5-amino-1-methylquinolinium iodide
IUPAC name	5-amino-1-methylquinolin-1-ium iodide
Molecular formula	C10H11IN2
Molecular weight	286.11 g/mol
CAS number	1158-64-1 (free cation; iodide salt assignments vary in the literature)
Origin	Synthetic small-molecule research probe; characterised as a potent NNMT inhibitor in the Neelakantan / Vedantham et al. medicinal-chemistry program (2018 Nature Chemical Biology)
Target	Nicotinamide N-Methyltransferase (NNMT) — SAM-dependent methyltransferase
Plasma half-life (research models)	~6 hours
Vial strengths (TogoPeptide)	50 mg lyophilized small-molecule powder (not a peptide; packaged similarly for laboratory research)

Origin and structure — small-molecule NNMT inhibitor

To understand why 5-Amino-1MQ exists as a research compound, it is worth first being precise about the enzyme it targets. NNMT (Nicotinamide N-Methyltransferase) is a cytosolic SAM-dependent methyltransferase expressed especially in adipose tissue and liver, with measurable expression in several other tissues. Its single enzymatic reaction is to transfer a methyl group from SAM onto the pyridine nitrogen of nicotinamide, producing 1-methylnicotinamide (1-MNA) and SAH. The reaction is metabolically expensive in two distinct senses simultaneously: nicotinamide is removed from the NAD+ salvage pathway (where it would otherwise be re-incorporated by NAMPT into NMN and ultimately back into NAD+), and SAM is consumed from the methyl-donor pool that supports cellular methylation reactions broadly — DNA methylation, histone methylation, protein methylation, and small-molecule biosynthesis.

Earlier work (Riederer et al., 2009; Kraus et al., 2014 Nature) established that NNMT expression is elevated in obese white adipose tissue and that genetic NNMT knockdown in research-mouse adipose tissue protected animals from diet-induced obesity, with parallel improvements in glucose homeostasis. That genetic-knockdown finding raised the obvious follow-up question: would pharmacological inhibition of NNMT reproduce the metabolic phenotype? Answering that question required selective small-molecule NNMT inhibitors. The medicinal-chemistry program reported by Neelakantan, Vedantham and colleagues in 2018 (Nature Chemical Biology) identified 5-Amino-1MQ as one of the most-potent membrane-permeable small-molecule NNMT inhibitors, with activity in NNMT enzymatic assays and reproducible metabolic effects in diet-induced-obese research-mouse models.

Structurally 5-Amino-1MQ is a quinolinium scaffold — a fused bicyclic aromatic system with a permanently-charged N-methylated quaternary nitrogen and a 5-amino substituent on the carbocyclic ring. The compound is supplied as the iodide salt for chemical stability and solubility, with formula C₁₀H₁₁IN₂ and molecular weight 286.11 g/mol. The cationic quinolinium head mimics the geometry of the methyl-acceptor nicotinamide pyridinium and the 1-MNA product, which is the design rationale for its competitive engagement of the NNMT active site.

Mechanism — NNMT inhibition and metabolic preservation

NNMT enzymatic inhibition

5-Amino-1MQ engages the NNMT active site competitively, occupying the nicotinamide-binding pocket and blocking productive methyl transfer from bound SAM. The published characterisation describes low-nM to mid-nM IC₅₀ values in NNMT enzymatic assays in the Neelakantan/Vedantham program, with selectivity over related SAM-dependent methyltransferases. Because the quinolinium head structurally mimics the pyridinium chemistry of the natural substrate, the compound functions as a substrate-analogue inhibitor — a classical medicinal-chemistry strategy for SAM-dependent methyltransferase targets.

NAD+ pool preservation

The downstream consequence of inhibiting NNMT is that nicotinamide is no longer consumed at the rate it otherwise would be. Nicotinamide is the salvage-pathway substrate for NAMPT, which converts it to NMN; NMNAT then converts NMN to NAD+. If NNMT activity is high, a large fraction of available nicotinamide is methylated to 1-MNA and excreted, removing that nicotinamide from the salvage pool. NNMT inhibition by 5-Amino-1MQ preserves the salvage substrate, with published research-cell-line work documenting increased intracellular NAD+ levels following NNMT inhibition. This is the mechanistic basis for framing 5-Amino-1MQ alongside direct NAD+ administration and NAD+ precursors (NMN, NR) as a third, mechanistically-distinct approach to elevating NAD+ availability.

SAM preservation and methylation

The parallel consequence is that SAM is no longer consumed by the NNMT reaction. SAM is the universal cellular methyl donor, supplying methyl groups for DNA methylation (DNMT enzymes), histone methylation (HMT enzymes), protein methylation, phospholipid biosynthesis, and small-molecule methylation broadly. When NNMT activity is high, SAM is being burned to produce 1-MNA — a methyl group expensive to synthesise that is exported and not recycled. By preserving SAM, 5-Amino-1MQ preserves the cellular methylation budget. This is the mechanism that connects NNMT inhibition to broader epigenetic-research framing: the methylation pool that supports gene-regulatory marks is itself sensitive to NNMT activity, and pharmacological NNMT inhibition is one of the cleaner research-tool routes to perturb the SAM-versus-SAH ratio in a controlled way.

Adipose-tissue research

The published research-animal-model literature documents 5-Amino-1MQ effects on adipose-tissue function, body weight, and glucose homeostasis in obesity research models. The original Kraus et al. 2014 Nature work used genetic NNMT knockdown to establish the protective phenotype against diet-induced obesity. The Neelakantan et al. 2018 Nature Chemical Biology program reproduced that phenotype with pharmacological NNMT inhibition by 5-Amino-1MQ, documenting reduced body weight, reduced adiposity, and improved metabolic markers in diet-induced-obese research mice. Subsequent research-program work has extended these readouts to additional adipose endpoints, mitochondrial markers, and gene-expression panels relevant to white-adipose-tissue metabolic function.

Adipose and metabolic research literature

The foundational paper for the entire NNMT-as-metabolic-target line is Kraus, Yang, Kong et al. 2014 Nature, which used adipose-specific NNMT knockdown in research-mouse models to demonstrate protection from diet-induced obesity. The phenotype was striking: knockdown animals on high-fat diets gained less weight, had improved glucose handling, and showed altered adipose-tissue gene-expression profiles consistent with elevated metabolic activity. This established NNMT as a genetically-validated metabolic target and motivated the medicinal-chemistry programs that followed.

The pharmacological-inhibitor follow-up is anchored in the Neelakantan et al. 2018 Nature Chemical Biology paper, which characterised 5-Amino-1MQ as a potent, selective, membrane-permeable NNMT inhibitor and reproduced the protective metabolic phenotype with the small molecule in diet-induced-obese research mice. Pissios 2017 (Trends in Endocrinology & Metabolism) provides the broader review context, framing NNMT as more than a vitamin-B3 clearance enzyme and synthesising the metabolic-research framing across genetic and pharmacological evidence. Subsequent work in the NNMT-inhibitor design field (Iyamu et al. and others) has continued to expand the structure-activity series and the catalogue of biological readouts.

Connection to longevity research

The research-frame connection from NNMT inhibition to longevity research is mediated by NAD+ and the sirtuin pathway. Sirtuins (SIRT1 through SIRT7) are NAD+-dependent deacylases central to the cellular-aging research literature; their activity is tightly linked to NAD+ availability. When NAD+ is depleted — as occurs with elevated NNMT activity, with chronological aging, or with metabolic stress — sirtuin activity falls. By preserving the nicotinamide pool feeding NAD+ salvage, 5-Amino-1MQ indirectly supports sirtuin-pathway research in the same way that NMN, NR, and direct NAD+ administration do, but through a mechanistically-different upstream lever.

This positions 5-Amino-1MQ as overlapping with the Longevity Stack research-compound space. Research designs combining 5-Amino-1MQ with NAD+ precursors, with sirtuin-pathway compounds, or with broader metabolic-aging research compounds all sit naturally in this overlap. The shared question across the space is the same: how does cellular NAD+ availability map onto sirtuin-mediated transcriptional programs and onto the metabolic-aging phenotype, and which pharmacological lever delivers the cleanest experimental separation?

Methylation-cycle research

The SAM-preservation arm of NNMT inhibition is the second research-frame entry point and is independently interesting. Cellular methylation reactions consume SAM at substantial flux: DNA methylation by DNMT1/3A/3B maintains and establishes 5-methylcytosine marks across the genome; histone methyltransferases write H3K4, H3K9, H3K27 and H3K36 methylation marks central to chromatin regulation; protein-arginine methyltransferases (PRMTs) and protein-lysine methyltransferases (PKMTs) methylate non-histone substrates; phosphatidylethanolamine methylation produces phosphatidylcholine; and small-molecule biosynthesis pathways (catecholamines, polyamines, creatine) consume SAM at the conversion step.

NNMT activity competes with all of these cellular methylation pathways for the same SAM pool. When NNMT activity is high, SAM is preferentially diverted to 1-MNA production — a methyl group exported and not recycled. NNMT inhibition preserves SAM availability for the broader methylation budget, with knock-on effects on the SAM/SAH ratio (the canonical thermodynamic readout for methylation potential) and on downstream methylation marks. This is what positions 5-Amino-1MQ inside the broader epigenetic-research framing: it is one of the cleaner research-tool levers for perturbing the SAM-pool side of the methylation balance without directly inhibiting any individual writer or eraser.

5-Amino-1MQ vs NAD+ vs NMN/NR — three approaches to NAD+ elevation

Compound class	Mechanism	Research framing
NAD+	Direct administration of the cofactor itself	Substrate replenishment; absorption + intracellular-uptake challenges are the dominant methodology question
NMN / NR	Salvage-pathway precursors — bypass NAMPT (NMN) or both NAMPT and NMNAT (NR) bottlenecks	Mainstream NAD+-research lever; large precursor literature, dominant in human-research programs
5-Amino-1MQ (NNMT inhibitor)	Inhibits the enzyme that drains nicotinamide from the salvage pool, preserving the existing precursor supply	Indirect NAD+ elevation via pool preservation; also preserves SAM, which the precursor approaches do not

The three approaches are complementary research tools rather than substitutes. Direct NAD+ administration tests the cofactor-availability hypothesis directly. NMN and NR test the salvage-pathway-precursor hypothesis. 5-Amino-1MQ tests the pool-preservation hypothesis — with the additional and mechanistically-distinct readout of preserving SAM in parallel with nicotinamide. Pairing 5-Amino-1MQ with an NAD+ precursor in parallel research arms allows direct dissection of “supply more substrate” versus “consume less substrate” as separable contributions to the same metabolic-research phenotype.

Storage and handling

5-Amino-1MQ ships as lyophilized small-molecule powder. Standard research-handling literature for stable quinolinium-class small molecules documents:

• Lyophilized state: sealed at −20°C, protected from light. Quinolinium salts are generally chemically stable in the dry state under these conditions.
• Diluent: 5-Amino-1MQ is typically reconstituted in sterile water or a dilute aqueous buffer for research use; the iodide salt is water-soluble. Bacteriostatic water is acceptable as a research diluent.
• Reconstituted state: refrigerate at 2–8°C immediately after reconstitution, protected from light.
• Chemical stability advantage: as a small molecule rather than a peptide, 5-Amino-1MQ is more chemically stable than the peptide research compounds in the rest of the catalog. There are no disulfide bridges to reduce, no proteolytic-degradation pathway concerns, and no cysteine-oxidation sensitivity. The dominant stability question is light protection and avoidance of strong oxidising or reducing conditions in the reconstitution diluent.
• Vial inspection: reconstituted solution should be clear; particulates indicate microbial compromise rather than aggregation in the peptide sense, and the vial should be discarded and re-reconstituted fresh.

Each TogoPeptide 5-Amino-1MQ shipment includes a per-batch Certificate of Analysis with HPLC purity (target ≥98%), mass-spectrometry identity confirmation, lot number, manufacture date and analysis date. See how to read a COA or reconstitution methodology for handling-protocol details.

Cross-research lines and pairings

5-Amino-1MQ fits naturally into the metabolic-aging research category alongside compounds with mechanistically-different but biologically-overlapping pathways. Common research-design pairings:

• 5-Amino-1MQ + NAD+ direct administration — pairing NNMT-inhibition (substrate preservation) with direct NAD+ administration (substrate supply) in parallel research arms allows dissection of “supply more” versus “consume less” as separable contributions to the same NAD+-availability phenotype.
• 5-Amino-1MQ + NMN/NR precursor — combining NNMT inhibition with salvage-pathway-precursor administration tests whether the two levers are additive or whether one saturates first; the SAM-preservation arm is unique to the NNMT-inhibitor side.
• 5-Amino-1MQ + MOTS-c — MOTS-c is the mitochondrial-derived peptide that activates AMPK and modulates metabolic homeostasis. Pairing AMPK activation (MOTS-c) with NNMT inhibition (5-Amino-1MQ) creates a dual-lever design covering both the energy-sensing arm and the NAD+/SAM-preservation arm of metabolic-aging research within the same experimental framework.
• Longevity research category — see the Longevity category listing for the full research-compound set, and the Fat Loss category for the metabolic-overlap compounds.
• Reconstitution standardisation — use the reconstitution calculator for stock-solution preparation when standardising concentration across research arms; small-molecule molar conversions differ from peptide conversions and accurate molecular-weight handling matters.

Closing

5-Amino-1MQ is a small molecule, not a peptide. It belongs in the metabolic-research compound deep-dive series because the biology it targets — NNMT-mediated co-consumption of nicotinamide and SAM — sits at the intersection of NAD+ research, methylation-cycle research, and adipose / metabolic-homeostasis research that defines the broader Longevity and Fat Loss research lines. The published research-animal-model literature documents reproducible body-weight and metabolic-marker improvements with NNMT inhibition; the foundational Kraus 2014 Nature genetic-knockdown work and the Neelakantan 2018 Nature Chemical Biology pharmacological-inhibitor work together establish the target as genetically and pharmacologically validated in research models.

Frame the use honestly. 5-Amino-1MQ is a research-tool compound for laboratory contexts in which the NNMT-inhibition mechanism is itself the scientific question. It is not an approved drug in any jurisdiction, not for human or veterinary use, and not therapeutic. This guide documents what published peer-reviewed research has investigated — structural and mechanism context for laboratory researchers, not protocol guidance, dosing recommendation, or clinical advice.

Source 5-Amino-1MQ for laboratory research:

• 5-Amino-1MQ product page — full identifiers, 50 mg vial, per-batch COA
• Longevity research compounds — full category listing
• Fat Loss research compounds — metabolic-overlap category

For methodology and laboratory-handling questions, contact our research-supply team at info@togopeptide.com.